HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $44 to $50.
July 26, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals' price target has been raised from $44 to $50 by HC Wainwright & Co. The firm maintains a Buy rating on the stock.
The news of a price target increase and maintained Buy rating by a reputable analyst firm like HC Wainwright & Co. is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100